Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mycophenolate or cyclosporine and methotrexate · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Standard of Care | ACTIVE_COMPARATOR | The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate. |
| Cyclosporine and Campath | EXPERIMENTAL | The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD. |
| Name | Type | Description |
|---|---|---|
| Alemtuzumab | DRUG | A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells. |
| mycophenolate or cyclosporine and methotrexate | DRUG | One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate |
Inclusion Criteria: * Diagnosis of a hematological malignancy * Peripheral blood as source of stem cells * Able to give informed consent * Availability of 6/6 matched sibling donor * Fit for transplant using a conventional or reduced intensity approach Exclusion Criteria: * AST/ALT \>3 x IULN at ...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 9 | PHASE3 | INCA034176, Ruxolitinib, Axatilimab |
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Belumosudil |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Ibrutinib |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |